Nuvation Bio Posts $41.9M Q4 Revenue, $529M Cash After Ibtrozi Launch
Nuvation Bio reported FDA approval and launch of Ibtrozi resulting in 432 patient starts by year-end, $41.9M in Q4 revenue and $529.2M cash after partnerships with Eisai and Nippon Kayaku. Johnson Fistel is probing potential federal securities claims against the company and its officers.
1. Ibtrozi Approval and Launch
Nuvation Bio secured FDA approval for Ibtrozi (taletrectinib) for ROS1-positive non-small cell lung cancer and executed a rapid commercial launch on March 2, 2026. The drug’s unique TRKB inhibition and favorable safety profile differentiate it from competitors, targeting intracranial disease control without severe neurological toxicities.
2. Commercial Performance and Financial Position
By year-end, Ibtrozi achieved 432 new patient starts, outpacing prior class launches sixfold, driving $41.9M in fourth-quarter revenue. The company strengthened its balance sheet to $529.2M in cash following international alliances with Eisai and Nippon Kayaku, positioning for broader first-line adoption in 2026.
3. Securities Investigation
Johnson Fistel, PLLP has initiated an inquiry into whether Nuvation Bio and its executives violated federal securities laws. The investigation centers on the timing and disclosure of clinical and financial developments that could have affected investor decisions.